Поиск патентов

05-01-2012 дата публикации

Bone-like prosthetic implants

Номер: US20120003185A1

Автор: Shai Meretzki

Принадлежит: Individual

A prosthetic implant comprising a biocompatible three-dimensional scaffold and at least two cell types selected from the group consisting of osteoblasts, osteoclasts, and endothelial cells or progenitors thereof.

Подробнее

Номер записи: 1

05-01-2012 дата публикации

Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy

Номер: US20120003229A1

Автор: Hervé Geneste, Wilfried Hornberger

Принадлежит: Individual

The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

Подробнее

Номер записи: 2

05-01-2012 дата публикации

Yeast ectopically expressing abnormally processed proteins and uses therefor

Номер: US20120003243A1

Автор: Susan L. Lindquist, Tiago Outeiro

Принадлежит: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

Disclosed are yeast ectopically expressing abnormally processed proteins and methods of screening to identify compounds that modulate the function of such abnormally processed proteins in yeast. Compounds identified by such screens can be used to treat or prevent diseases associated with abnormally processed proteins or protein misfolding. Such diseases include Parkinson's Disease, Parkinson's Disease with accompanying dementia, Lewy body dementia, Alzheimer's disease with Parkinsonism, and multiple system atrophy.

Подробнее

Номер записи: 3

05-01-2012 дата публикации

Anti-inflammatory dissolvable film

Номер: US20120003292A1

Автор: Aron J. Saffer, William Zev Levine, Zvi G. Loewy

Принадлежит: Individual

Provided, among other things, is a slowly dissolvable film comprising: herbal bioactive agent(s); and polymer(s), dissolvable in the aggregate, wherein the film becomes adhesive as it is placed against a mucosal surface and begins to absorb moisture therefrom.

Подробнее

Номер записи: 4

05-01-2012 дата публикации

Solid Dosage Forms Of Bendamustine

Номер: US20120003309A1

Автор: Jeffrey Colledge, Margaretha Olthoff, Taoufik Ouatas, Thomas Alfred Profitlich, Ulrich Patzak

Принадлежит: ASTELLAS DEUTSCHLAND GMBH

In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.

Подробнее

Номер записи: 5

05-01-2012 дата публикации

Dpp iv inhibitor formulations

Номер: US20120003313A1

Автор: Anja Kohlrausch, Gerd Seiffert, Patrick Romer

Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Подробнее

Номер записи: 6

05-01-2012 дата публикации

Method of reducing multi-drug resistance using inositol tripyrophosphate

Номер: US20120003327A1

Автор: Claudine Kieda, Jean-Marie Lehn, Yves Claude Nicolau

Принадлежит: Individual

Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.

Подробнее

Номер записи: 7

05-01-2012 дата публикации

Modulators of atp-binding cassette transporters

Номер: US20120004216A1

Автор: Ashvani K. Singh, Lewis R. Makings, Mark T. Miller, Matthew Hamilton, Peter D.J. Grootenhuis, Sara S. Hadida Ruah, Thomas Cleveland

Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее

Номер записи: 8

05-01-2012 дата публикации

Novel tetrahydro-quinoline derivatives

Номер: US20120004218A1

Автор: HongYing Yun, Li Chen, Lichun Feng, Mengwei Huang, Mingwei Zhou, Yongfu Liu, Yun He

Принадлежит: Hoffmann La Roche Inc

A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein A 1 to A 3 and R 1 to R 10 have the significance given in claim 1 , can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes and cancers.

Подробнее

Номер записи: 9

05-01-2012 дата публикации

Triheterocyclic Compounds and Compositions Thereof

Номер: US20120004224A1

Автор: Elisc Rioux, Giorgio Attardo, Jean-Francois Lavallee, Sasmita Tripathy, Terrance W. Deyle

Принадлежит: Gemin X Pharmaceuticals Canada Inc

The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.

Подробнее

Номер записи: 10

05-01-2012 дата публикации

Organic compounds

Номер: US20120004247A1

Автор: Brian Cox, Robin Alec Fairhurst, Roger John Taylor

Принадлежит: NOVARTIS AG

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

Подробнее

Номер записи: 11

05-01-2012 дата публикации

Methods of using a methylxanthine compound

Номер: US20120004248A1

Автор: Clifford S. Deutschman, Richard J. Levy

Принадлежит: Deutschman Clifford S, Levy Richard J

The invention relates to compositions and methods for treating various diseases or medical conditions by administering a methylxanthine compound. Specifically, the invention relates to compositions and methods for treating cytochrome oxidase (CcOX) mediated diseases or medical conditions by administering compositions comprising a methyl xanthine compound.

Подробнее

Номер записи: 12

05-01-2012 дата публикации

Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy

Номер: US20120004251A1

Автор: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura

Принадлежит: GW Pharma Ltd, Otsuka Pharmaceutical Co Ltd

This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

Подробнее

Номер записи: 13

05-01-2012 дата публикации

New ccr2 receptor antagonists and uses thereof

Номер: US20120004252A1

Автор: Christofer Tautermann, Christoph Hoenke, Heiner Ebel, Kai Gerlach, Marco Santagostino, Riccardo Giovannini, Rocco Mazzaferro, Sara Frattini, Stefan Scheuerer, Thomas Trieselmann

Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

Подробнее

Номер записи: 14

05-01-2012 дата публикации

Method of treatment or prophylaxis

Номер: US20120004259A1

Автор: Bruce Douglas Wyse, Maree Therese Smith

Принадлежит: SPINIFEX PHARMACEUTICALS PTY LTD

The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT 2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects. The AT 2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of neuropathic conditions.

Подробнее

Номер записи: 15

05-01-2012 дата публикации

Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia

Номер: US20120004395A1

Автор: Adriano Fontana, Christoph Kundig, Mike Recher

Принадлежит: MED DISCOVERY SA, Universitaet Zuerich

The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.

Подробнее

Номер записи: 16

12-01-2012 дата публикации

Solid composition containing bacillus-type non-pathogenic bacterial spores

Номер: US20120009167A1

Автор: Tiziano Prato

Принадлежит: Sanofi Aventis SpA

The invention relates to a composition of spores of nonpathogenic bacteria of the Bacillus genus, adsorbed onto a matrix made up of at least one water-insoluble adsorbent compound and a cellulose derivative, which can be obtained by the fluidized air bed technique, useful in the pharmaceutical, veterinary and nutrition fields.

Подробнее

Номер записи: 17

12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1

Автор: Anton Mayr, Barbara Mayr

Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее

Номер записи: 18

12-01-2012 дата публикации

Recombinant surfactant protein d compositions and methods of use thereof

Номер: US20120010126A1

Автор: Howard Clark, Kenneth Bannerman Milne Reid, Palaniyar Nadesalingam, Peter Strong

Принадлежит: Medical Research Council

We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Подробнее

Номер записи: 19

12-01-2012 дата публикации

Novel uses of vegfxxxb

Номер: US20120010138A1

Автор: Andrew Salmon, David Owen Bates, Steven James Harper

Принадлежит: University of Bristol

The invention provides VEGF xxx b, or an agent which selectively promotes the expression of VEGF xxx b in preference to VEGF xxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGF xxx b in a host organism, for use in treating or preventing microvascular hyperpermeability disorders, or in regulating the pro-angiogenic pro-permeability properties of VEGF xxx isoforms, or in supporting epithelial cell survival without increased permeability, or in reducing the nature (for example the number density and/or size) of fenestrations of epithelial filtration membranes in vivo or in vitro.

Подробнее

Номер записи: 20

12-01-2012 дата публикации

Natriuretic activities

Номер: US20120010142A1

Автор: John C. Burnett, Jr., Timothy M. Olson

Принадлежит: Mayo Foundation for Medical Education and Research

This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.

Подробнее

Номер записи: 21

12-01-2012 дата публикации

Lactoferrin compositions and methods of wound treatment

Номер: US20120010150A1

Автор: Atul Varadhachary, Jose Engelmayer

Принадлежит: Agennix Inc

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Подробнее

Номер записи: 22

12-01-2012 дата публикации

Tumor necrosis factor inhibiting peptides and uses thereof

Номер: US20120010158A1

Автор: Rahul Jain, Rajesh Jain, Shudhanand Prasad, Shweta Dubey, Vijay Goel, Virendra Kumar Vinayak

Принадлежит: Panacea Biotec Ltd

The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.

Подробнее

Номер записи: 23

12-01-2012 дата публикации

"Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates"

Номер: US20120010170A1

Автор: George R. Painter

Принадлежит: Individual

A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conugate compound is CMX001, having formula (I) or a pharmaceutically acceptable salt thereof.

Подробнее

Номер записи: 24

12-01-2012 дата публикации

11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds

Номер: US20120010194A1

Автор: Henrik Sune Andersen, Soren Ebdrup

Принадлежит: High Point Pharnaceuticals LLC

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Подробнее

Номер записи: 25

12-01-2012 дата публикации

Anthranilamide derivatives as pesticides

Номер: US20120010250A1

Автор: Arnd Voerste, Christoph Grondal, Ernst Rudolf Gesing, Heinz-Juergen Wroblowsky, Markus Heil, Rüdiger Fischer, Ulrich Görgens

Принадлежит: Bayer CropScience AG

The present invention relates to novel anthranilamide derivatives of the general formula (I) in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, Q, Y and n are each as defined in the description—, to the use thereof as insecticides and acaricides for control of animal pests, and to several processes for preparation thereof.

Подробнее

Номер записи: 26

12-01-2012 дата публикации

Choline and tromethamine salt of licofelone

Номер: US20120010261A1

Автор: Hans-Günter Striegel, Stefan Laufer, Wolfgang Albrecht

Принадлежит: CAIR Biosciences GmbH

The present invention relates to the choline and tromethamine salt of Licofelone.

Подробнее

Номер записи: 27

12-01-2012 дата публикации

Acetylene derivatives having mglur 5 antagonistic activity

Номер: US20120010263A1

Автор: Fabrizio Gasparini, Kasper Zimmerman, Silvio Ofner, Terance William Hart, Yves Auberson

Принадлежит: Individual

The invention provides compounds of formula I wherein n, A, R, R′, R″, R O , X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.

Подробнее

Номер записи: 28

12-01-2012 дата публикации

Modulation of anxiety through blockade of anandamide hydrolysis

Номер: US20120010283A1

Автор: Andrea Duranti, Andrea Tontini, Daniele Piomelli, Giorgio Tarzia, Marco Mor

Принадлежит: Universita degli Studi di Parma, Universita degli Studi di Urbino "Carlo Bo", UNIVERSITY OF CALIFORNIA

Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

Подробнее

Номер записи: 29

12-01-2012 дата публикации

Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Номер: US20120010295A1

Автор: Daniel Lucius Vasella, Randy Lee Webb, William Hewitt

Принадлежит: Daniel Lucius Vasella, Randy Lee Webb, William Hewitt

The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.

Подробнее

Номер записи: 30

12-01-2012 дата публикации

Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound

Номер: US20120010405A1

Автор: Daisuke Tanaka, Toshiyuki Negoro

Принадлежит: Individual

The present invention provides a compound of the formula (III): wherein R is a C 1-6 alkyl group, as a novel optically active intermediate for preparing tetrahydropyrrolo[1,2-a]pyrazin-4-spiro-3′-pyrrolidine derivatives such as Ranirestat being a promising therapeutic agent for diabetic complications in a short process, in an economically advantageous manner and in high yields, and the process for preparing the same.

Подробнее

Номер записи: 31

19-01-2012 дата публикации

Methods and compositions for cns delivery of heparan n-sulfatase

Номер: US20120014936A1

Автор: Brian Vernaglia, Farah Natoli, Gaozhong Zhu, Jamie Tsung, Jennifer Terew, Jing Pan, Pericles Calias, Richard Pfeifer, YUAN Jiang, Zahra Shahrokh

Принадлежит: Shire Human Genetics Therapies Inc

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Подробнее

Номер записи: 32

19-01-2012 дата публикации

Il-1beta binding antibodies and fragments thereof

Номер: US20120014967A1

Автор: Arnold Horwitz, Gang Chen, Linda Masat, Marina Roell, Mary Haak-Frendscho

Принадлежит: Xoma Technology Ltd USA

An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

Подробнее

Номер записи: 33

19-01-2012 дата публикации

PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS

Номер: US20120014989A1

Автор: Andrew P. Combs, Haisheng Wang, James D. Rodgers, Richard B. Sparks

Принадлежит: Incyte Corp

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Подробнее

Номер записи: 34

19-01-2012 дата публикации

Enterically coated cysteamine, cystamine and derivatives thereof

Номер: US20120015038A1

Автор: Jerry Schneider, Ranjan Dohil

Принадлежит: UNIVERSITY OF CALIFORNIA

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Подробнее

Номер записи: 35

19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1

Автор: Stephen Tomlinson, V. Michael Holers

Принадлежит: MUSC Foundation for Research Development, University of Colorado

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее

Номер записи: 36

19-01-2012 дата публикации

Kallikrein-inhibitor therapies

Номер: US20120015881A1

Автор: Anthony Williams, Arthur C. Ley, Luigi Bergamaschini, Maria Grazia De Simoni, Robert C. Ladner, Shirish Hirani

Принадлежит: Dyax Corp

Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

Подробнее

Номер записи: 37

19-01-2012 дата публикации

Novel compounds as cannabinoid receptor ligands

Номер: US20120015929A1

Автор: Arturo Perez Medrano, Jennifer M. Frost, Karin Rose Marie Tietje, Meena V. Patel, Sridhar Peddi, Steven P. Latshaw, Teodozyj Kolasa, William A. Carroll, Xueqing Wang

Принадлежит: ABBOTT LABORATORIES

Disclosed herein are compounds of formula (I) wherein R 1 , R 2 , R 3 , R 25a , R 26a , X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.

Подробнее

Номер записи: 38

19-01-2012 дата публикации

Mek mutations conferring resistance to mek inhibitors

Номер: US20120015973A1

Автор: Carlos Garcia Echeverria, Caroline Emery, Levi A. Garraway

Принадлежит: Dana Farber Cancer Institute Inc, NOVARTIS AG

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.

Подробнее

Номер записи: 39

19-01-2012 дата публикации

(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors

Номер: US20120015994A1

Автор: Bertil Samuelsson, Guo-Qiang Lin, Hans Wallberg, Kevin Parkes, Ming-Hua Xu, Piaoyang Sun, Tony Johnson, Xin-Sheng Lei

Принадлежит: Medivir AB

The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).

Подробнее

Номер записи: 40

19-01-2012 дата публикации

RNAi MOLECULE TARGETING THYMIDYLATE SYNTHASE AND APPLICATION THEREOF

Номер: US20120016012A1

Автор: Cheng Long HUANG, Hiromi Wada

Принадлежит: Delta Fly Pharma Inc

This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises the nucleotide sequence shown in SEQ ID NO: 2. The invention also provides an antitumor agent comprising such RNAi molecule and a 5-FU antitumor agent.

Подробнее

Номер записи: 41

19-01-2012 дата публикации

Method for Synthesizing Pirfenidone

Номер: US20120016133A1

Автор: Michael Cyr, Ramachandran Radhakrishnan, Sabine M. Pyles

Принадлежит: Intermune Inc

A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.

Подробнее

Номер записи: 42

19-01-2012 дата публикации

Enzymes and methods for producing omega-3 fatty acids

Номер: US20120016144A1

Автор: Anne Maree Mackenzie, Craig Christopher Wood, Dion Matthew Frederick Frampton, James Robertson Petrie, Peter David Nichols, Peter Maged Mansour, Pushkar Shrestha, Qing Liu, Stanley Suresh Robert, Surinder Pal Singh, Susan Irene Ellis Blackburn, Xue-Rong Ziiou

Принадлежит: Individual

The present invention relates generally to the field of recombinant fatty acid synthesis, particularly in transgenic plants. The application describes genes involved in fatty acid synthesis and provides methods and vectors for the manipulation of fatty acid composition of plant oils. In particular, the invention provides constructs for achieving the integration of multiple heterologous genes involved in fatty acid synthesis into the plant genome, such that the resulting plants produce altered levels of polyunsaturated fatty acids. Also described are methods for enhancing the expression of fatty acid biosynthesis enzymes by co-expressing a silencing suppressor within the plant storage organ.

Подробнее

Номер записи: 43

19-01-2012 дата публикации

Diastereoisomers of hypophosphorous acid derivatives

Номер: US20120016155A1

Автор: Chelliah Selvam, Francine Acher, Jean-Philippe Pin

Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

The invention relates to the diastereoisomers of hypophosphorous acid derivatives, having formula (I), wherein the phenyl group is substituted by one or several atoms or groups, occupying one or several positions on the phenyl ring, and a method for the separation thereof.

Подробнее

Номер записи: 44

26-01-2012 дата публикации

Densensitizing dentifrice exhibiting dental tissue antibacterial agent uptake

Номер: US20120020900A1

Автор: Guofeng Xu, Ravi Subramanyam

Принадлежит: Colgate Palmolive Co

An oral composition exhibiting increased uptake by dental tissue of antibacterial compounds contained therein and eliminating or substantially reducing the discomfort and pain associated with dentinal hypersensitivity. The composition includes an orally acceptable vehicle for such composition, an effective therapeutic amount of an antibacterial compound, a mixture of anionic surfactant and amphoteric surfactant, the mixture having 0.1 wt. % to 2.0 wt. % anionic surfactant and 0.8 wt. % to 2.0 wt. % amphoteric surfactant, and a potassium ion releasable compound.

Подробнее

Номер записи: 45

26-01-2012 дата публикации

Methods for accelerating wound healing by administration of adipokines

Номер: US20120020917A1

Автор: Inessa Solomonik, Liora Braiman-Wiksman

Принадлежит: Individual

Methods for inducing or accelerating a healing process of a damaged skill or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or transforming the skin cells colonizing the damaged skin or skin wound such as to express and secrete an adipokine, thereby inducing or accelerating the healing process of the damaged skin or skin wound.

Подробнее

Номер записи: 46

26-01-2012 дата публикации

Thermosensitive hydrogel composition and method

Номер: US20120020932A1

Автор: Archit Sanghvi, Jian Q. Yao, Jizong Gao, Xiao Huang

Принадлежит: Zimmer Orthobiologics Inc

A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment.

Подробнее

Номер записи: 47

26-01-2012 дата публикации

Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects

Номер: US20120020951A1

Автор: Curtis Thompson, Gregory I. Frost, Harold Michael Shepard, Xiaoming Li

Принадлежит: Individual

Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.

Подробнее

Номер записи: 48

26-01-2012 дата публикации

Garcinia Mangostana L. and Iridoid Based Formulations

Номер: US20120021079A1

Автор: Afa Kehaati Palu, Brett Justin West, Claude Jarakae Jensen, Jeffery A. Wasden, Shixin Deng

Принадлежит: Individual

Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Garcinia mangostana L. and iridoids.

Подробнее

Номер записи: 49

26-01-2012 дата публикации

Combination of an insulin and a glp-1-agonist

Номер: US20120021978A1

Автор: Barbel Rotthauser, Christopher James Smith, Ulrich Werner

Принадлежит: Sanofi Aventis Deutschland GmbH

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.

Подробнее

Номер записи: 50

26-01-2012 дата публикации

Bridged compounds as hiv integrase inhibitors

Номер: US20120022045A1

Автор: Boyoung Kim, Dai-Shi Su, H. Marie LOUGHRAN, John Lim, John S. Wai, Mark W. Embrey, Peter D. Williams, Richard C.A. Isaacs, Shankar Venkatraman, Wayne Thompson

Принадлежит: Individual

Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X1, X2, χ3, Y, Z, R1, R2 and R3 are defined herein. The N compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Подробнее

Номер записи: 51

26-01-2012 дата публикации

Histamine h3 inverse agonists and antagonists and methods of use thereof

Номер: US20120022050A1

Автор: Kerry L. Spear, Milan Chytil, Qun Kevin Fang, Sharon R. Engel

Принадлежит: SUNOVION PHARMACEUTICALS INC

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Подробнее

Номер записи: 52

26-01-2012 дата публикации

Novel cyanopyrimidine derivative

Номер: US20120022077A1

Автор: Daisaku Michikami, Hiroyuki Yamazaki, Hisashi Shinohara, Keisuke Hino, Kuni Ito, Norifumi Sato, Yasuhiro Takeji, Yohei Yuki

Принадлежит: Otsuka Pharmaceutical Co Ltd

The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.

Подробнее

Номер записи: 53

26-01-2012 дата публикации

Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof

Номер: US20120022102A1

Автор: Alpesh Pravinchandra SHAH, Dhimant Jasubhai Patel, SHRIPRAKASH DHAR Dwivedi

Принадлежит: Cadila Healthcare Ltd

The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.

Подробнее

Номер записи: 54

26-01-2012 дата публикации

Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex

Номер: US20120022116A1

Автор: Haibei Hu, Haiyan Sun, Huayun Deng, Mingqian He, Weijun Niu, YE Fang

Принадлежит: Corning Inc

Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):

Подробнее

Номер записи: 55

26-01-2012 дата публикации

Heterocyclic antagonists of prostaglandin d2 receptors

Номер: US20120022119A1

Автор: Brian Andrew Stearns, Jeffrey Roger Roppe, John Howard Hutchinson, Nicholas Simon Stock, Timothy Parr

Принадлежит: Amira Pharmaceuticals Inc

Described herein are heteroaryl compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Подробнее

Номер записи: 56

26-01-2012 дата публикации

Pyrrolidine triple reuptake inhibitors

Номер: US20120022125A1

Автор: Jianguo Ma, Liming Shao

Принадлежит: SUNOVION PHARMACEUTICALS INC

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Подробнее

Номер записи: 57

26-01-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120022139A1

Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker

Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее

Номер записи: 58

02-02-2012 дата публикации

Cancer therapy based on tumor associated antigens derived from cyclin d1

Номер: US20120027684A1

Автор: Harpreet Singh, Steffen Walter, Toni Weinschenk

Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

Подробнее

Номер записи: 59

02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1

Автор: Andrew Nixon, Anthony Williams, Daniel J. Sexton, Qi-Long Wu, Robert C. Ladner

Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее

Номер записи: 60

02-02-2012 дата публикации

Methods for treating diabetes

Номер: US20120027729A1

Автор: Darwin J. Prockop, Min Jeong Seo, Ryang Hwa Lee

Принадлежит: Tulane University

Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs.

Подробнее

Номер записи: 61

02-02-2012 дата публикации

Method of preparing lipid nanoparticles

Номер: US20120027825A1

Автор: Alyaa Adel Ramadan, Jean-Pierre Benoit, Olivier Thomas, Patrick Saulnier

Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM, Universite dAngers

The present invention relates to a useful method for preparing nanocapsules having a liquid lipid core and a solid shell and charged with at least one active agent having a hydrophilic character, said method comprising at least the steps consisting in: i) providing at least a first microemulsion having a water-in-oil character, stabilized by at least one lipophilic surfactant and containing in its hydrophilic phase at least one active agent having a hydrophilic character, providing at least a second microemulsion, separate from the first microemulsion, formulated by phase inversion of an emulsion and stabilized by at least one heat-sensitive, nonionic hydrophilic surfactant; iii) adding said first microemulsion to said second microemulsion under conditions propitious for the formation of a novel microemulsion architecture in which said hydrophilic active agent remains present in the hydrophilic phase of the first microemulsion; and iv) chill-hardening the mixture formed in the previous step, so as to obtain nanocapsules comprising said hydrophilic active agent and being formed from a lipid core, which is liquid at room temperature, and encapsulated in a film which is solid at room temperature. Further, the invention relates to nanocapsules which are able to be obtained by said method.

Подробнее

Номер записи: 62

02-02-2012 дата публикации

Whitefly Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof

Номер: US20120028300A1

Автор: Dean Ervin Cress, Jianzhong Zhang, Subba Reddy Palli, Tarlochan Singh Dhadialla

Принадлежит: Intrexon Corp

The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

Подробнее

Номер записи: 63

02-02-2012 дата публикации

Apj receptor compounds

Номер: US20120028888A1

Автор: Athan Kuliopulos, Jay Janz, Thomas J. Mcmurry

Принадлежит: ANCHOR THERAPEUTICS Inc

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

Подробнее

Номер записи: 64

02-02-2012 дата публикации

Pyrazole compounds as crth2 antagonists

Номер: US20120028938A1

Автор: Christoph Hoenke, Dieter Wolfgang Hamprecht, Domnic Martyres, Peter Seither, Ralf Anderskewitz, Thorsten Oost, Wolfgang Rist

Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Подробнее

Номер записи: 65

02-02-2012 дата публикации

Biomarker assays for detecting or measuring inhibition of tor kinase activity

Номер: US20120028972A1

Автор: Jian-hua DING, Lilly Wong, Shuichan Xu

Принадлежит: Signal Pharmaceuticals LLC

Provided herein are methods for detecting and/or measuring the inhibition of TOR kinase activity in a subject and uses associated therewith.

Подробнее

Номер записи: 66

02-02-2012 дата публикации

Novel compound having 3-heteroarylpyrimidin-4-(3h)-one structure and pharmaceutical preparation containing same

Номер: US20120028983A1

Автор: Gen Watanabe, Hitomi Aoki, Junya Tagashira, Kazuhiro Onogi, Rie Ishida, Ryohei Sekimoto, Seiichi Sato, Tadaaki Ohgiya, Toru Miura

Принадлежит: Kowa Co Ltd

Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R 1 and R 2 independently represent a C 1-6 alkyl group; and each of R 3 to R 5 is absent or represents H, a halogen atom, OH, NO 2 , a halo-C 1-6 alkyl group, a (substituted) C 1-6 alkoxy group, a (substituted) C 3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]

Подробнее

Номер записи: 67

02-02-2012 дата публикации

7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof

Номер: US20120029044A1

Автор: Gwenaella Rescourio, Jurg R. Pfister, Meenakshi S. Venkatraman, Xiaoming Zhang

Принадлежит: Theron Pharmaceuticals Inc

Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.

Подробнее

Номер записи: 68

02-02-2012 дата публикации

Crystalline form of sunitinib and processes for its preparation

Номер: US20120029046A1

Автор: Bharati Choudhari, Mahesh Hublikar, Prakash Bansode, Vinayak Gore

Принадлежит: Generics UK Ltd

The present invention relates to a novel crystalline form of sunitinib free base designated form I and to processes for its preparation. The invention also relates to its use as an API and in the preparation of various forms of sunitinib. Further, the invention relates to pharmaceutical compositions comprising the novel crystalline form and salts, solvates and hydrates prepared according to the invention, and to the uses of said pharmaceutical compositions in the treatment and/or prevention of cancer.

Подробнее

Номер записи: 69

02-02-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120029052A1

Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker

Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее

Номер записи: 70

02-02-2012 дата публикации

Compositions for treating or preventing obesity and insulin resistance disorders

Номер: US20120029065A1

Автор: David A. Sinclair, Maria Alexander-Bridges

Принадлежит: General Hospital Corp, Harvard College

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

Подробнее

Номер записи: 71

02-02-2012 дата публикации

Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids

Номер: US20120029079A1

Автор: Charles R. Wolf, Clifford R. Elcombe

Принадлежит: CXR Biosciences Ltd

The molecules of formula (I) are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipis of eicosanoid status or functions may be desirable. Formula (I): Z 1 —Z 1 —Z 2 wherein a) Z 1 represents CO 2 H or a derivative thereof; b) Z 2 represents F, H, —CO 2 H or a derivative thereof; and c) X represents fluorinated alkylene; or a solvate thereof, for example a perfluorinated fatty acid or derivative thereof.

Подробнее

Номер записи: 72

02-02-2012 дата публикации

Novel Crystalline Form of Atorvastatin Hemi-calcium Salt, Hydrate Thereof, And Method of Producing The Same

Номер: US20120029207A1

Автор: Do Yeon Oh, Doo Seong Choi, Hoe Joo Son, Kyung Ju Lee, Sun Ho Chang

Принадлежит: KYONGBO PHARM

The present invention provides a novel crystalline form of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1, which is known to be useful as a drug, a hydrate thereof and a preparation method thereof:

Подробнее

Номер записи: 73

09-02-2012 дата публикации

Dry powder formulation comprising a phosphodiesterase inhibitor

Номер: US20120031403A1

Автор: Daniela Cocconi, Francesca Schiaretti, Roberto Bilzi

Принадлежит: Chiesi Farmaceutici SpA

Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD.

Подробнее

Номер записи: 74

09-02-2012 дата публикации

Treatment of neurotrophic factor mediated disorders

Номер: US20120034193A1

Автор: Antonia Orsi, Daryl Rees, Patrick Howson, Yaer Hu, Zongqin Xia

Принадлежит: Phytopharm Ltd

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Подробнее

Номер записи: 75

09-02-2012 дата публикации

Compositions for potentiating apoposis signals in tumour cells

Номер: US20120034210A1

Автор: Anne-Marie Vacher, Benjamin Chaigne-Delalande, Laurence Bepoldin, Patrick Legembre, Pierre Soubeyran, Pierre Vacher

Принадлежит: Institut Bergonié, Universite Victor Segalen Bordeaux 2

The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5.

Подробнее

Номер записи: 76

09-02-2012 дата публикации

Method of Administering an Antibody

Номер: US20120034243A1

Автор: David Edward Allison, Judith A. Fox, Lee R. Brettman

Принадлежит: Genentech Inc, Millennium Pharmaceuticals Inc

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.

Подробнее

Номер записи: 77

09-02-2012 дата публикации

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

Номер: US20120034244A1

Автор: Alessandro FATATIS, Nathan Graeme DOLLOFF, Nick LOIZOS

Принадлежит: ImClone LLC, Philadelphia Health and Education Corp

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Подробнее

Номер записи: 78

09-02-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity

Номер: US20120034251A1

Автор: Hiromi Kumon, Masami Watanabe, Yasutomo Nasu, Yuji Kashiwakura

Принадлежит: Momotaro Gene Inc

According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.

Подробнее

Номер записи: 79

09-02-2012 дата публикации

Dentifrice composition and method of use

Номер: US20120034282A1

Автор: Evangelia Arvanitidou, Joe Vazquez, Mary Horchos, Qing Claire He, Thomas Boyd, Ying Yang

Принадлежит: Colgate Palmolive Co

An exfoliating dentifrice composition is described that contains a plurality of granules and an orally acceptable vehicle. The granules include at least one polymeric binding agent. The composition includes at least one abrasive agent having an average particle diameter of 0.01 mm to 4 mm. Also included are methods of exfoliating an oral cavity soft tissue by use of the composition.

Подробнее

Номер записи: 80

09-02-2012 дата публикации

Cell lines producing blocking antibodies to human RANKL

Номер: US20120034690A1

Автор: Dirk M. Anderson

Принадлежит: Immunex Corp

Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

Подробнее

Номер записи: 81

09-02-2012 дата публикации

Combination of compounds for treating or preventing skin diseases

Номер: US20120035123A1

Автор: André Jomard, Laurent Fredon, Olivier Roye

Принадлежит: Galderma Research and Development SNC

A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described.

Подробнее

Номер записи: 82

09-02-2012 дата публикации

Modulators of Cellular Adhesion

Номер: US20120035154A1

Автор: Johan D. Oslob, Kenneth Barr, Min Zhong, Wang Shen

Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Подробнее

Номер записи: 83

09-02-2012 дата публикации

Process for preparation of high-purity meloxicam and meloxicam potassium salt

Номер: US20120035162A1

Автор: Balázs VOLK, Eniko Molnar, Éva Pécsi, György Krasznai, Györgyi VERECZKEYNÉ DONÁTH, Gyula LUKÁCS, Gyula Simig, Gyuláné Körtvélyessy, Kalman Nagy, Márta PORCS-MAKKAY, Norbert Mesterházy, Tibor Mezei, Valéria HOFMANNÉ FEKETE

Принадлежит: Individual

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Подробнее

Номер записи: 84

09-02-2012 дата публикации

Antiparasitic agent for fish and method of controlling proliferation of fish parasites

Номер: US20120035181A1

Автор: Fumi Kawano, Noritaka Hirazawa

Принадлежит: Nippon Suisan Kaisha Ltd

A method of controlling proliferation of fish parasites comprising the administration of 1 to 50 mg/kg fish body weight/day of an inhibitor of folate synthesis and/or an inhibitor of folate activation to fish continuously for 1 to 2 weeks. Using a combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is preferable, and a sulfonamide is preferable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist, etc., can be used as the inhibitor of folate activation. The antiparasitic agent is able to exterminate fish parasites via oral administration. It is particularly effective against parasites belonging to the ciliate group among fish parasites.

Подробнее

Номер записи: 85

09-02-2012 дата публикации

Compounds useful as inhibitors of atr kinase

Номер: US20120035407A1

Автор: Jean-Damien Charrier, Michael O'donnell, Philip Michael Reaper, Ronald Marcellus Alphonsus Knegtel, Steven John Durrant

Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula II: wherein the variables are as defined herein.

Подробнее

Номер записи: 86

16-02-2012 дата публикации

Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Номер: US20120039874A1

Автор: Katsunari Tezuka, Nobuaki Hori, Takashi Tsuji

Принадлежит: Japan Tobacco Inc

Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

Подробнее

Номер записи: 87

16-02-2012 дата публикации

Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof

Номер: US20120039899A1

Автор: Andres G. Grandea, III, Christina L. Boozer, Ole Olsen

Принадлежит: Theraclone Sciences Inc

The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.

Подробнее

Номер записи: 88

16-02-2012 дата публикации

Anti-Adhesion Alginate Barrier of Variable Absorbance

Номер: US20120039959A1

Автор: Eva Esser, Joerg Tessmar, Lukas Bluecher, Michael T. Milbocker, Thomas Reintjes

Принадлежит: MAST Biosurgery AG

Described are mono- and bi-layer alginate post-surgical anti-adhesion barriers with tailored absorption profiles and non-migrating characteristics. Muco-adhesive properties of alginates in their solid state are used to localize the device, and lubricious properties of alginates in their liquid state are used to mitigate adhesion formation during wound healing. In addition, the design of the implant can be selected such that the crosslinking agent is released from the device under specific conditions and the absorbance profile modified. A medicinal agent may optionally be incorporated.

Подробнее

Номер записи: 89

16-02-2012 дата публикации

Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use

Номер: US20120039980A1

Автор: David M. Gravett, George Y. Daniloff, Jacqueline Schroeder, Louis C. Sehl, Olof Mikael Trollsas, Philip M. Toleikis

Принадлежит: AngioDevice International GmbH

Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.

Подробнее

Номер записи: 90

16-02-2012 дата публикации

Novel biomaterials, their preparation and use

Номер: US20120040901A1

Автор: Christian Schoch, György Lajos KIS, Jozsef Szejtli, Lajos Szente

Принадлежит: Individual

The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components. The further components incorporated into the precipitates can be pharmaceutical compounds, pesticides, agrochemicals, colorants, diagnostics, enzymes, foodstuffs etc.

Подробнее

Номер записи: 91

16-02-2012 дата публикации

Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes

Номер: US20120040909A1

Автор: Emmanuel Bourinet, Fabrice Marger, Joël Nargeot, Michel Lazdunski, Pierre Escoubas

Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Universite de Nice Sophia Antipolis UNSA

A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

Подробнее

Номер записи: 92

16-02-2012 дата публикации

Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders

Номер: US20120040940A1

Автор: Daniel Cohen, Ilya Chumakov, Nathalie Cholet, Oxana Guerassimenko, Serguei Nabirochkin

Принадлежит: Pharnext SA

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.

Подробнее

Номер записи: 93

16-02-2012 дата публикации

Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof

Номер: US20120040984A1

Автор: Christophe Philippo, Claudie Namane, Eric Nicolai, Eykmar Fett, Patrick Mougenot

Принадлежит: SANOFI SA

The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.

Подробнее

Номер записи: 94

16-02-2012 дата публикации

Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs

Номер: US20120040995A1

Автор: Chris J. Novotny, Danny Chung Hsu, Diana C. West, Paul J. Hergenrother, Quinn Patrick Peterson, Timothy M. Fan

Принадлежит: University of Illinois

Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.

Подробнее

Номер записи: 95

16-02-2012 дата публикации

Benzimidazoles which have activity at m1 receptor and their uses in medicine

Номер: US20120041027A1

Автор: David Gwyn Cooper, Graham Walker, Ian Thomson Forbes, Jian Jin, Paul Adrian Wyman, Vincenzo Garzya, Yann Louchart

Принадлежит: Glaxo Group Ltd

Compounds of formula (I) and salts and solvates are provided: wherein Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Подробнее

Номер записи: 96

16-02-2012 дата публикации

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Номер: US20120041031A1

Автор: Daniel W. Gil, John E. Donello, Lauren M.B. Luhrs, Veena Viswanath

Принадлежит: Allergan Inc

Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.

Подробнее

Номер записи: 97

16-02-2012 дата публикации

Substituted acylguanidine derivatives (as amended)

Номер: US20120041036A1

Автор: Isao Kinoyama, Takehiro Miyazaki, Takuya Washio, Yohei Koganemaru

Принадлежит: Astellas Pharma Inc

An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT 5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT 5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

Подробнее

Номер записи: 98

23-02-2012 дата публикации

Composition and Methods for the Diagnosis and Treatment of Tumor

Номер: US20120045390A1

Автор: Frederic J. Desauvage, William I. Wood, Zemin Zhang

Принадлежит: Genentech Inc

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Подробнее

Номер записи: 99

23-02-2012 дата публикации

Engineered anti-il-13 antibodies, compositions, methods and uses

Номер: US20120045438A1

Автор: Alexey V. Teplyakov, Ellen Chi, Gopalan Raghunathan, Hong Mimi Zhou, Jill Giles-Komar, Jill M. Carton, Johan Fransson, Juan C. Almagro, Karyn T. O'neil, Linus Hyun, Ronald V. Swanson, Shanrong Zhao, Wendy Cordier, Yiqing Feng

Принадлежит: Centocor Ortho Biotech Inc

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Подробнее

Номер записи: 100

Настройки

Небесная энциклопедия

Мониторинг СМИ

Форма поиска